Arvinas Analyst Ratings
BenzingaApr 15 07:24 ET
Piper Sandler Sticks to Their Buy Rating for Arvinas Holding Company (ARVN)
TipRanksApr 12 08:29 ET
Arvinas Analyst Ratings
BenzingaApr 12 07:14 ET
Analysts Offer Insights on Healthcare Companies: Prime Medicine, Inc. (PRME), Arvinas Holding Company (ARVN) and Viridian Therapeutics (VRDN)
TipRanksApr 12 07:10 ET
Buy Rating Affirmed for Arvinas Amid Strategic Novartis Deal and Growth Potential
TipRanksApr 11 13:05 ET
Arvinas Analyst Ratings
BenzingaMar 25 12:04 ET
Arvinas Holding Company: A Buy Rating on Strong Clinical Pipeline and Promising Trial Outcomes
TipRanksMar 1 00:58 ET
Arvinas Holding Company: Buy Rating Backed by Promising Breast Cancer Therapy and Strategic Expansion Into Parkinson's Disease Treatment
TipRanksFeb 28 07:36 ET
Arvinas Analyst Ratings
BenzingaFeb 28 07:32 ET
Buy Rating Affirmed for Arvinas Holding Company Amid Strong Drug Candidate Prospects and Robust Financial Health
TipRanksFeb 28 05:40 ET
Arvinas Holding Company: A Strong Buy on Robust Clinical Data and Strategic Trial Advancements
TipRanksFeb 27 15:46 ET
Arvinas Analyst Ratings
BenzingaFeb 15 11:02 ET
Citi Downgrades Arvinas to Neutral, Cites Valuation
Seeking AlphaFeb 14 15:55 ET
Arvinas Analyst Ratings
BenzingaFeb 14 08:33 ET
Arvinas Holding Company: A Promising Buy Amidst Progressive Drug Development and Strategic Collaborations
TipRanksFeb 8 05:46 ET
Arvinas Analyst Ratings
BenzingaFeb 1 07:03 ET
Goldman Sachs Initiates Buy Rating on Arvinas With a Focus on Innovative Cancer Treatments and Strategic Growth Potential
TipRanksFeb 1 02:25 ET
Analysts Are Bullish on These Healthcare Stocks: Arvinas Holding Company (ARVN), Pacira Pharmaceuticals (PCRX)
TipRanksJan 7 21:30 ET
Wells Fargo Upgrades Arvinas to Overweight Ahead of Phase 3 Data Readout
Seeking AlphaDec 19, 2023 13:36 ET
Wells Fargo Upgrades Arvinas to Overweight, Announces $63 Price Target
BenzingaDec 19, 2023 07:02 ET
No Data
No Data